In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...

Researchers have discovered the antibody 04_A06, which neutralizes the human immunodeficiency virus (HIV) in almost all ...

The FDA has granted Fast Track designation to Bristol Myers Squibb’s anti-MTBR-tau antibody (BMS-986446) for the treatment of early Alzheimer disease.

Patients with severe asthma receiving mepolizumab experience reductions in healthcare resource use and improvements in work ...

LD Micro is dedicated to being the definitive resource in the small-cap space. From its industry-recognized index and robust data to hosting some of the most influential events each year, LD Micro’s ...

Leap Therapeutics ( ($LPTX) ) has shared an update. On October 6, 2025, Leap Therapeutics entered into a Securities Purchase Agreement for a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an ...

Leqembi Iqlik, a subcutaneous formation of lecanemab, is now available as a maintenance dosing regimen for the treatment of early Alzheimer disease.

Omalizumab is indicated for the treatment of persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies and ...